Comparative Pharmacology
Head-to-head clinical analysis: EMTRICITABINE versus LAMIVUDINE TENOFOVIR DISOPROXIL FUMARATE NEVIRAPINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMTRICITABINE versus LAMIVUDINE TENOFOVIR DISOPROXIL FUMARATE NEVIRAPINE.
EMTRICITABINE vs LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE; NEVIRAPINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nucleoside reverse transcriptase inhibitor; phosphorylated to emtricitabine triphosphate which competes with endogenous deoxycytidine triphosphate and incorporates into viral DNA causing chain termination.
Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) that inhibits HIV-1 reverse transcriptase via DNA chain termination after intracellular phosphorylation to lamivudine triphosphate. Tenofovir disoproxil fumarate is a nucleotide reverse transcriptase inhibitor (NtRTI) that, after hydrolysis and phosphorylation, inhibits HIV-1 reverse transcriptase by competing with deoxyadenosine 5'-triphosphate and causing DNA chain termination. Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that directly binds to and inhibits HIV-1 reverse transcriptase, causing a conformational change and reducing enzyme activity.
200 mg orally once daily, typically in combination with other antiretroviral agents.
One tablet (300 mg lamivudine, 300 mg tenofovir disoproxil fumarate, 400 mg nevirapine) orally once daily. Nevirapine requires a 14-day lead-in dose of 200 mg once daily when initiating therapy.
None Documented
Clinical Note
moderateEmtricitabine + Ribavirin
"Emtricitabine may increase the hepatotoxic activities of Ribavirin."
Clinical Note
moderateLamivudine + Emtricitabine
"The risk or severity of adverse effects can be increased when Lamivudine is combined with Emtricitabine."
Clinical Note
moderateGanciclovir + Emtricitabine
"The risk or severity of adverse effects can be increased when Ganciclovir is combined with Emtricitabine."
Clinical Note
moderateValganciclovir + Emtricitabine
None Documented
Terminal elimination half-life is approximately 10 hours (range 8–12 hours) in adults with normal renal function; prolonged to >20 hours in severe renal impairment (CrCl <30 mL/min).
Lamivudine: 5-7 hours in adults (extended to 20-30 hours in renal impairment). Tenofovir: 17-18 hours in adults (prolonged in renal impairment). Nevirapine: ~45 hours (single dose) to 25-30 hours (multiple doses due to autoinduction).
Renal: approximately 86% of the dose is excreted unchanged in urine via glomerular filtration and active tubular secretion. Biliary/fecal: minimal (<14% as unchanged drug and metabolites in feces).
Lamivudine: 70% renal (glomerular filtration and tubular secretion) as unchanged drug. Tenofovir: 70-80% renal (glomerular filtration and tubular secretion) as unchanged drug. Nevirapine: ~81% renal (metabolites, <5% unchanged), ~10% fecal.
Category C
Category A/B
Antiretroviral, NRTI
NRTI
"The risk or severity of adverse effects can be increased when Valganciclovir is combined with Emtricitabine."